Taken together, this study suggests that enzalutamide may be combined with the STAT3 inhibitor GPB730 in order to enhance the efficacy of anti-androgen treatment, offering an additional therapeutic approach for advanced prostate cancer. Here, STAT3 is linked to prostate cancer.